Xinqing Lin Guihuan Qiu Fang Li Haiyi Deng Yinyin Qin Xiaohong Xie Juhong Jiang Yong Song Ming Liu Chengzhi Zhou
10.3389/fimmu.2021.683202
Front Immunol
2021 Jun 2;12:683202.
immunotherapy metachronous multiple primary lung cancer (mmplc) next-generation sequencing (ngs) re-biopsy resistance
CC BY
https://pubmed.ncbi.nlm.nih.gov/34149722/
B7-H1 Antigen / antagonists & inhibitors Biomarkers, Tumor / antagonists & inhibitors Drug Substitution Immune Checkpoint Inhibitors / therapeutic use Molecular Targeted Therapy Neoplasms, Multiple Primary / diagnosis Neoplasms, Multiple Primary / drug therapy
B7-H1 Antigen / antagonists & inhibitors Biomarkers, Tumor / antagonists & inhibitors Drug Substitution Immune Checkpoint Inhibitors / therapeutic use Molecular Targeted Therapy Neoplasms, Multiple Primary / diagnosis Neoplasms, Multiple Primary / drug therapy Case Reports Research Support, Non-U.S. Gov't Aged, 80 and over Female Humans Immune Checkpoint Inhibitors / administration & dosage Immune Checkpoint Inhibitors / adverse effects Immunohistochemistry Neoplasms, Multiple Primary / etiology Programmed Cell Death 1 Receptor / antagonists & inhibitors Symptom Assessment Tomography, X-Ray Computed Treatment Outcome B7-H1 Antigen Biomarkers, Tumor CD274 protein, human Immune Checkpoint Inhibitors PDCD1 protein, human Programmed Cell Death 1 Receptor
PMC8207139
34149722
Case Report: A Rare Case of Metachronous Multiple Primary Lung Cancers in a Patient With Successful Management by Switching From Anti-PD-1 Therapy to Anti-PD-L1 Therapy
2021